After Daiichi (DSNKY) presented initial Phase 1 data from HR+/HER2- BC cohort for Trop2-ADC competitor Dato-DXd at SABCS, Piper Sandler analyst Do Kim said the data "were similar to possibly better than prior Trodelvy results," but added that Gilead’s (GILD) Trodelvy remains two years ahead of Dato-DXd in that indication. Kim, who expects Trodelvy to maintain its BC lead by eventual expansion into earlier lines, has an Overweight rating and $96 price target on Gilead shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GILD:
- Arcellx Soars on Key Deal with Gilead’s Kite
- ImmunoGen Joins hands with Gilead on AML Therapy
- Gilead’s Kite Pharma, Daiichi Sankyo announce partnership revision
- Kite, Daiichi Sankyo announces changes to Yescarta licensing deal in Japan
- Cantor biotech/biopharma analysts hold an analyst/industry conference call